Investigating metformin for cancer prevention and treatment: the end of the beginning.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Discovery

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-12-0263PMID 22926251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma.

  2013cited by this paper
• Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects

  2013cited by this paper
• A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers

  2013cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

  2012cited by this paper
• Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

  2012cited by this paper
• Statin Use as a Moderator of Metformin Effect on Risk for Prostate Cancer Among Type 2 Diabetic Patients

  2012cited by this paper
• Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer

  2012cited by this paper
• Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?

  2012cited by this paper
• Diabetes, metformin use, and colorectal cancer survival in women: A retrospective cohort study.

  2012cited by this paper
• Abstract LB-345: Differences in metformin transporter expression between breast tumor and breast cancer cell lines: selecting a relevant breast cancer cell model for metformin therapy

  2012cited by this paper
• Cellular Responses to the Metal-Binding Properties of Metformin

  2012cited by this paper
• Examining the effects of metformin on survival outcome in stage II/III colorectal cancer patients with diabetes mellitus.

  2012cited by this paper
• Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage

  2012cited by this paper
• The insulin and insulin-like growth factor receptor family in neoplasia: an update

  2012cited by this paper
• Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis

  2012cited by this paper
• Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.

  2012cited by this paper
• Mortality After Incident Cancer in People With and Without Type 2 Diabetes

  2012cited by this paper
• Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC

  2012cited by this paper
• Acute testosterone deprivation reduces insulin sensitivity in men

  2012cited by this paper
• Abstract 3561: Effects of metformin on markers of insulin resistance and on breast cancer proliferation: The putative role of IGFBP-1 as a predictive biomarker

  2012cited by this paper
• Cellular and molecular mechanisms of metformin: an overview.

  2012cited by this paper
• Distinct perturbation of the translatome by the antidiabetic drug metformin

  2012cited by this paper
• Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.

  2012cited by this paper
• Metformin in early breast cancer (BC): A prospective, open-label, neoadjuvant “window of opportunity” study.

  2012cited by this paper
• Dual effects of metformin on breast cancer proliferation in a randomized trial.

  2012cited by this paper
• Diabetes, metformin, and breast cancer in postmenopausal women.

  2012cited by this paper
• Hyperactivation of 4E-Binding Protein 1 as a Mediator of Biguanide-Induced Cytotoxicity during Glucose Deprivation

  2012cited by this paper
• Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes

  2012cited by this paper
• Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.

  2012cited by this paper
• Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer

  2012cited by this paper
• Metformin and pancreatic cancer: a clue requiring investigation.

  2012cited by this paper
• Defining the Contribution of AMP-activated Protein Kinase (AMPK) and Protein Kinase C (PKC) in Regulation of Glucose Uptake by Metformin in Skeletal Muscle Cells*

  2012cited by this paper
• Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer

  2012cited by this paper
• MortalityAfter Incident Cancer in People With andWithout Type 2 Diabetes Impact of metformin on survival

  2012cited by this paper
• Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy: A Population-Based Cohort Study

  2012cited by this paper
• Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership.

  2012cited by this paper
• Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer

  2012cited by this paper
• Cancer occurrence in Danish diabetic patients: duration and insulin effects

  2012cited by this paper
• Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians

  2012cited by this paper
• Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway.

  2012cited by this paper
• Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation.

  2012cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.

  2012cited by this paper
• Abstract 1010: Effect of dietary energy balance modulation on the ability of metformin to inhibit skin tumor promotion

  2012cited by this paper
• AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress

  2012cited by this paper
• Phenformin as prophylaxis and therapy in breast cancer xenografts

  2012cited by this paper
• Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

  2012cited by this paper
• Of mice and men: The benefits of caloric restriction, exercise, and mimetics

  2012cited by this paper
• Metformin pathways: pharmacokinetics and pharmacodynamics

  2012cited by this paper
• The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase

  2012cited by this paper
• AMPK: a nutrient and energy sensor that maintains energy homeostasis

  2012cited by this paper
• Metformin abolishes increased tumor 18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet

  2011cited by this paper
• Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics

  2011cited by this paper
• Relevance of the OCT1 transporter to the antineoplastic effect of biguanides.

  2011cited by this paper
• Reductive carboxylation supports growth in tumor cells with defective mitochondria

  2011cited by this paper
• Structure of the membrane domain of respiratory complex I

  2011cited by this paper
• Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models

  2011cited by this paper
• Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

  2011cited by this paper
• Lapatinib Activity in Premalignant Lesions and HER-2–Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial

  2011cited by this paper
• Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo

  2011cited by this paper
• Regulation of cancer cell metabolism

  2011cited by this paper
• Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

  2011cited by this paper
• CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors

  2011cited by this paper
• Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

  2011cited by this paper
• Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion

  2011cited by this paper
• Targeting cancer metabolism: a therapeutic window opens

  2011cited by this paper
• Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)

  2011cited by this paper
• Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial

  2011cited by this paper
• Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.

  2011cited by this paper
• Insulin increases de novo steroidogenesis in prostate cancer cells.

  2011cited by this paper
• Abstract 4366: The telomere targeting agent sodium metaarsenite can eradicate the side population of hormone resistant prostate cancer cells

  2011cited by this paper
• Otto Warburg's contributions to current concepts of cancer metabolism

  2011cited by this paper
• Promoter-specific effects of metformin on aromatase transcript expression.

  2011cited by this paper
• Metformin Represses Self-Renewal of the Human Breast Carcinoma Stem Cells via Inhibition of Estrogen Receptor-Mediated OCT4 Expression

  2011cited by this paper
• Diabetes, cancer, and metformin: connections of metabolism and cell proliferation

  2011cited by this paper
• Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

  2011cited by this paper
• Otto Warburg's contributions to current concepts of cancer metabolism

  2011cited by this paper
• IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

  2011cited by this paper
• Metformin inhibits P‐glycoprotein expression via the NF‐κB pathway and CRE transcriptional activity through AMPK activation

  2011cited by this paper
• Use of Metformin Is Not Associated with a Decreased Risk of Colorectal Cancer: A Case–Control Analysis

  2011cited by this paper
• Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.

  2010cited by this paper
• Diabetes and Cancer

  2010cited by this paper
• Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1

  2010cited by this paper
• Metformin and Other Biguanides in Oncology: Advancing the Research Agenda

  2010cited by this paper
• Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis

  2010cited by this paper
• The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.

  2010cited by this paper
• Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.

  2010cited by this paper
• Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial

  2010cited by this paper
• Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

  2010cited by this paper
• Diabetes and Cancer: A Consensus Report

  2010cited by this paper
• Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

  2010cited by this paper
• Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes

  2010cited by this paper
• Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• Towards the molecular mechanism of respiratory complex I.

  2010cited by this paper
• Enhancing CD8 T-cell memory by modulating fatty acid metabolism

  2009cited by this paper
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer.

  2009cited by this paper
• Histological evaluation of AMPK signalling in primary breast cancer

  2009cited by this paper

• Signaling pathways and targeted interventions for precancers

  2026cites this paper
• Metformin and Oncogenic Pathways: Crosstalk Between Energy Sensing and Tumor Progression.

  2026cites this paper
• A study of oral metformin for the intravesical treatment of non‐muscle‐invasive bladder cancer

  2025cites this paper
• Metformin May Improve Intestinal Mucosal Barrier Function and Help Prevent and Reverse Colorectal Cancer in Mice

  2025cites this paper
• Therapeutic Potential of Anti‐Diabetes Drugs and Anti‐Dyslipidemia Drugs to Mitigate Head and Neck Cancer Risk in Metabolic Syndrome

  2025cites this paper
• Metformin reverses 5-FU chemoresistance by downregulating DKK1, WNT5A, and ABCB1 expressions in gastric cancer: An experimental and bioinformatic study

  2025cites this paper
• Proteasomal Dysfunction in Cancer: Mechanistic Pathways and Targeted Therapies

  2025cites this paper
• Metformina em Combinação Com Inibidores de Checkpoints Imunológicos: A Captação Miocárdica de FDG Pode Prever o Prognóstico?

  2025cites this paper
• Metformin's Anticancer Odyssey: Revealing Multifaceted Mechanisms Across Diverse Neoplastic Terrains- A Critical Review.

  2025cites this paper
• Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab

  2025cites this paper
• Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies

  2025cites this paper
• Chemoprevention of Gastrointestinal Cancers: An Umbrella Review of Meta‐Analyses of Randomized Controlled Trials and Cohort Studies

  2025cites this paper
• Therapeutic potential of metformin-based combination therapy in acute myeloid leukemia

  2025cites this paper
• Effect of metformin on hypoxia-associated gene expression in oral cavity squamous cell carcinoma in non-diabetic patients - a prospective window of opportunity study

  2025cites this paper
• Antitumor Effects of Metformin in Squamous Cell Carcinoma under Leptin Treatment Conditions

  2025cites this paper
• Lipids: Driving Forces in the Underlying Biology of Carcinogenesis.

  2025cites this paper
• Expression patterns of PIK3CA and PTEN in cancer and type 2 diabetes mellitus.

  2025cites this paper
• Metformin in Colorectal Cancer: Epidemiological Evidence, Predictive Biomarkers, and Implications for Prevention and Treatment

  2025cites this paper
• The evaluation of the effects of metformin on the rat testes at a light and electron microscopic level.

  2025cites this paper
• Metformin in Combination with Immune Checkpoint Inhibitors: Myocardial FDG Uptake Can Predict Prognosis?

  2025cites this paper
• A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.

  2025cites this paper
• Ovarian Aging: Mechanisms, Age‐Related Disorders, and Therapeutic Interventions

  2025cites this paper
• Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: a phase II, randomized study

  2025cites this paper
• The Role of Metformin in cancer Prevention and Treatment: A Game Changer?

  2025cites this paper
• Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

  2025cites this paper
• Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group

  2024cites this paper
• Small molecules targeting mitochondria as an innovative approach to cancer therapy.

  2024cites this paper
• Metformin inhibits migration and epithelial-to-mesenchymal transition in non-small cell lung cancer cells through AMPK-mediated GDF15 induction.

  2024cites this paper
• Senescence and senolysis in cancer: The latest findings

  2024cites this paper
• Metabolic plasticity in pancreatic cancer: The mitochondrial connection

  2024cites this paper
• Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis

  2024cites this paper
• Findings on Age at Onset of Cancer in Diabetic and Non-diabetic Populations

  2024cites this paper
• The role of mitochondria in metastasis development.

  2024cites this paper
• Chemoprevention of head and neck cancer: a review of current approaches and future perspectives.

  2024cites this paper
• Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma

  2024cites this paper
• Metformin Effects on SHIP2, AMPKs and Gut Microbiota: Recent Updates on Pharmacology.

  2024cites this paper
• Mitochondrial inhibitors: a new horizon in breast cancer therapy

  2024cites this paper
• Metformin use and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada

  2024cites this paper
• Repurposing metformin as a potential anticancer agent using in silico technique

  2024cites this paper
• Biochemical hallmarks-targeting antineoplastic nanotherapeutics

  2024cites this paper
• Aqueous anion binder for phenolate and nitro substituted phenolates through second-sphere coordination network

  2024cites this paper
• Metforminium 5-fluorouracilate: The first codrug molecular salt of 5-fluorouracil demonstrating perfected in vitro/vivo characteristics and synergic antitumor effects

  2024cites this paper
• The Effect of Different Glucose Concentrations on the Antiproliferative Activity of Metformin in MCF-7 Breast Cancer Cells

  2023cites this paper
• EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.

  2023cites this paper
• Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis

  2023cites this paper
• Metformin may improve the outcome of patients with colorectal cancer and type 2 diabetes mellitus partly through effects on neutrophil extracellular traps

  2023cites this paper
• The mechanisms of action of mitochondrial targeting agents in cancer: inhibiting oxidative phosphorylation and inducing apoptosis

  2023cites this paper
• Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial

  2023cites this paper
• Mechanism of sorafenib resistance associated with ferroptosis in HCC

  2023cites this paper
• The Impact of Metformin on Tumor-Infiltrated Immune Cells: Preclinical and Clinical Studies

  2023cites this paper
• In Reply to Hsu and Shueng.

  2023cites this paper
• Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer

  2023cites this paper
• Targeting immuno-oncology metabolism for precision cancer therapy

  2023cites this paper
• STAT3 as a therapeutic target in the metformin-related treatment.

  2023cites this paper
• Recent advances of mitochondrial complex I inhibitors for cancer therapy: Current status and future perspectives.

  2023cites this paper
• Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review

  2023cites this paper
• Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance.

  2023cites this paper
• Nutrient Condition in the Microenvironment Determines Essential Metabolisms of CD8+ T Cells for Enhanced IFNγ Production by Metformin

  2022cites this paper
• Identification of the Highly Active, Species Cross-Reactive Complex I Inhibitor BAY-179.

  2022cites this paper
• A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes

  2022cites this paper
• Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.

  2022cites this paper
• Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

  2022cites this paper
• A functional screen with metformin identifies microRNAs that regulate metabolism in colorectal cancer cells

  2022cites this paper
• Efficacy of metformin on protein profile in breast tumor cells by assessment in vitro and in silico analysis In vitro ve in silico analizi ile metforminin meme tümörü hücrelerinde protein

  2022cites this paper
• Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer

  2022cites this paper
• Metformin Bicarbonate-Mediated Efficient RNAi for Precise Targeting of TP53 Deficiency in Colon and Rectal Cancers.

  2022cites this paper
• Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer.

  2022cites this paper
• Метформин и злокачественные новообразования: возможный механизм противоопухолевого действия и перспективы использования в практике

  2022cites this paper
• Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting Hexokinase-II

  2022cites this paper
• Research progress on the therapeutic effect and mechanism of metformin for lung cancer

  2022cites this paper
• Effects of metabolic cancer therapy on tumor microenvironment

  2022cites this paper
• Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis

  2022cites this paper
• Senescence and cancer — role and therapeutic opportunities

  2022cites this paper
• The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis

  2022cites this paper
• Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model

  2022cites this paper
• Polypharmacy in Oncology.

  2022cites this paper
• Metformin and Cancer: Is this the end?

  2022cites this paper
• Fatores de risco associados a neoplasia de sistema nervoso central

  2021cites this paper
• Repurposing metformin for the treatment of gastrointestinal cancer

  2021cites this paper
• Metformin Dysregulates the Unfolded Protein Response and the WNT/β-Catenin Pathway in Endometrial Cancer Cells through an AMPK-Independent Mechanism

  2021cites this paper
• Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation

  2021cites this paper
• Pitavastatin and metformin synergistically activate apoptosis and autophagy in pancreatic cancer cells

  2021cites this paper
• Proteomic Analysis Reveals That Metformin Suppresses PSMD2, STIP1, and CAP1 for Preventing Gastric Cancer AGS Cell Proliferation and Migration

  2021cites this paper
• Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

  2021cites this paper
• Lipid Metabolism in Cancer Cells.

  2021cites this paper
• First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer

  2021cites this paper
• Neuroprotective Effects of Long-Term Metformin Preconditioning on Rats with Ischemic Brain Injuries

  2021cites this paper
• Queueing theory model of Krebs cycle

  2021cites this paper
• Phenformin and ataxia‐telangiectasia mutated inhibitors synergistically co‐suppress liver cancer cell growth by damaging mitochondria

  2021cites this paper
• DMSO_A_326378 3673..3689

  2021cites this paper
• Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?

  2021cites this paper
• Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis

  2021cites this paper
• Biguanides: Species with versatile therapeutic applications.

  2021cites this paper
• Obesity and Aging: Molecular Mechanisms and Therapeutic Approaches.

  2021cites this paper
• Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line

  2021cites this paper
• The Current and Potential Therapeutic Use of Metformin—The Good Old Drug

  2021cites this paper
• Metformin: review of epidemiology and mechanisms of action in pancreatic cancer

  2021cites this paper
• Metformin combined with local irradiation provokes abscopal effects in a murine rectal cancer model

  2021cites this paper
• Hyaluronic Acid Conjugated Metformin-Phospholipid Sonocomplex: A Biphasic Complexation Approach to Correct Hypoxic Tumour Microenvironment

  2021cites this paper
• Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study

  2021influential citation